Oncology

  • ISU104(Barecetamab)

    Mechanism
    of Action
    Anti-ErbB3 mAb
    View Detail
    • Target Discovery
    • Pre-clinical
    • Phase 1
    • Phase 2
    • Phase 3
    Head and Neck Cancer
    60%
    Colorectal Cancer
    36%
    Breast Cancer
    36%
  • ISU104 CAR-NK

    Mechanism
    of Action
    Anti-ErbB3 mAb + CAR-NK
    Partner
    한국생명공학연구원
    View Detail
    • Target Discovery
    • Pre-clinical
    • Phase 1
    • Phase 2
    • Phase 3
    Leukemia, Solid Tumors
    15%
  • ABX2001

    Mechanism
    of Action
    Pro-cytokine
    View Detail
    • Target Discovery
    • Pre-clinical
    • Phase 1
    • Phase 2
    • Phase 3
    Solid Tumors
    4%

Rare Disease

  • ISU304(Dalcinonacog Alfa)

    Mechanism
    of Action
    SC Prophylactic Factor IX
    Partner
    CATALYST BIOSCIENCES
    View Detail
    • Target Discovery
    • Pre-clinical
    • Phase 1
    • Phase 2
    • Phase 3
    Hemophilia B
    80%
  • ISU305(Eculizumab)

    Mechanism
    of Action
    Anti-C5 mAb
    Partner
    PHARMASYNTEZ
    View Detail
    • Target Discovery
    • Pre-clinical
    • Phase 1
    • Phase 2
    • Phase 3
    Paroxysmal Nocturnal Hemoglobinuria (PNH), and other Autoimmune Diseases
    60%
  • ISU203

    Mechanism
    of Action
    Anti-ASM mAb
    Partner
    KNU산학협력단
    View Detail
    • Target Discovery
    • Pre-clinical
    • Phase 1
    • Phase 2
    • Phase 3
    Dementia by Alzheimer's Disease
    22%